NASDAQ$CCRN

Cross Country Healthcare Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

Cross Country Healthcare's Q4 2019 financial results were announced, revealing a year-over-year revenue increase of 7% and sequential increase of 3%.

Cross Country Healthcare reported a revenue increase of 7% year-over-year and 3% sequentially. The company's net loss attributable to common shareholders was $1.1 million, and diluted EPS was a loss of $0.03 per share. Adjusted EBITDA was $8.3 million, and adjusted EPS was $0.07.

  • Consolidated revenue increased by 7% year-over-year and 3% sequentially, reaching $215.1 million.
  • Net loss attributable to common shareholders was $1.1 million, a significant improvement from the prior year's $19.7 million loss.
  • Adjusted EBITDA improved to $8.3 million, representing 3.9% of revenue.
  • Adjusted EPS was $0.07, compared to $0.00 in the prior year.

Headline financials

Total Revenue

$215M

Previous: $201M+7.1%
EPS (adj)

$0.07

Previous: -$0.55+112.6%
Nurse/Allied FTEs

7.3K

Previous: 7.1K+4.0%
Rev per FTE per Day

$284.00

Previous: $276.00+2.9%
Physician Days Filled

11.7K

Previous: 11.7K+0.1%
Rev per Day Filled

$1.71K

Previous: $1.57K+9.5%
Capital Expenditures

$898K

Previous: $1.19M-24.7%
Free Cash Flow

-$6.25M

Previous: -$1.95M-220.1%
Net Income

-$1.14M

Previous: -$19.7M+94.2%
Operating Income

$1.95M

Previous: -$24.1M+108.1%
Gross Profit

$53.2M

Previous: $50.6M+5.1%
Cash & Equivalents

$1.03M

Previous: $16M-93.6%
Total Assets

$382M

Previous: $427M-10.5%
Stock-Based Comp

$879K

Previous: $1.21M-27.4%

Revenue & EPS history

Cross Country Healthcare · Revenue · Quarterly

$215M

Q4 2019+7.1%vs Q4 2018
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

Cross Country Healthcare · $211M total across 2 segments · Q4 2019

  • Nurse and Allied Staffing
    $191M+6.9%
  • Physician Staffing
    $20M+9.6%

Forward guidance

The company provided guidance for the first quarter of 2020, with revenue expected to be between $207 million and $212 million.

Tailwinds

  • Revenue is expected to be between $207 million and $212 million.
  • Year-over-year revenue change is projected to be 6% - 9%.
  • Adjusted EBITDA is expected to be between $4.5 million and $5.5 million.
  • Year-over-year Adjusted EBITDA change is projected to be 25% - 52%.
  • Adjusted EPS is expected to be between $(0.03) and $0.00.

Headwinds

  • Sequential revenue change is projected to be (4)% - (1)%.
  • Gross Profit Margin is expected to be 23.0% - 23.5%.
  • Gross Profit Margin change is projected to be (170) bps - (120) bps both year-over-year and sequentially.
  • Sequential Adjusted EBITDA change is projected to be (46)% - (34)%.
  • Adjusted EPS is expected to be between $(0.03) and $0.00.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

-2.7%

Avg return

Earnings day

-1.5%

Avg return

5 days after

+0.5%

Avg return

30 days after

44%

28 / 64 earnings

Positive

+24.6%

Q3 2021

Best reaction

-33.6%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+0.4%+0.8%
Q4 2025+8.2%+7.9%+0.5%
Q3 2025-14.1%-7.2%-32.9%
Q1 2025+0.4%+0.8%-6.7%
Q4 2024+0.3%-6.0%-13.9%
Q3 2024+7.2%-6.1%+57.9%
Q2 2024-2.7%-8.2%-17.3%
Q1 2024-4.9%-9.0%-14.1%
Q4 2023-2.7%-0.3%+5.7%
Q3 2023-14.0%-19.0%-10.7%
Q2 2023-14.7%-14.0%-3.8%
Q1 2023+5.1%+9.9%+26.1%
Q4 2022-5.6%+3.2%-13.2%
Q3 2022-2.5%-11.3%-2.8%
Q2 2022-13.7%-14.1%-7.6%
Q1 2022-2.6%-7.1%+0.9%
Q4 2021-1.5%+6.6%+2.4%
Q3 2021+24.6%+18.0%+21.1%
Q2 2021+23.0%+14.6%+29.7%
Q1 2021+16.5%+24.0%+17.4%
Q4 2020+18.9%+24.6%+33.8%
Q3 2020-5.0%-3.0%+9.3%
Q2 2020+9.6%+4.7%+1.6%
Q1 2020-4.8%-2.0%+7.6%
Q4 2019+0.4%-12.2%-27.7%
Q3 2019+14.2%+16.9%+10.9%
Q2 2019-0.8%-5.5%+5.6%
Q1 2019+4.7%+18.7%+0.9%
Q4 2018-3.6%-11.6%-22.5%
Q3 2018+7.8%+3.4%+2.7%
Q2 2018-30.9%-26.0%-14.7%
Q1 2018-16.7%-11.0%-4.3%
Q4 2017-18.8%-13.6%-15.8%
Q3 2017-9.6%-13.8%-2.6%
Q2 2017+3.1%+1.2%+2.5%
Q1 2017-13.0%-15.1%-16.7%
Q4 2016+3.4%-5.3%-7.2%
Q3 2016+22.9%+24.3%+31.7%
Q2 2016-11.5%-17.0%-14.2%
Q1 2016+10.0%
Q4 2015-21.9%
Q3 2015+9.5%
Q2 2015+10.1%
Q1 2015-4.6%
Q4 2014-9.6%
Q3 2014-0.5%
Q2 2014+1.8%
Q1 2014-14.3%
Q4 2013-22.3%
Q3 2013+3.1%
Q2 2013-3.3%
Q1 2013+0.4%
Q4 2009-5.5%
Q3 2012-0.9%
Q2 2012-5.5%
Q1 2011-3.1%
Q1 2012+11.8%
Q4 2011+0.8%
Q3 2010+2.5%
Q3 2011+2.5%
Q2 2011-33.6%
Q4 2010-33.6%
Q2 2010-33.6%
Q1 2010-7.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro